ATR

Business Context and Reporting Period

Company: AptarGroup, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: AptarGroup is a leading global supplier of innovative dispensing systems (pumps, closures, and aerosol valves) for personal care, fragrance/cosmetic, pharmaceutical, household, and food/beverage markets. The company operates through three reportable segments: Beauty & Home, Closures, and Pharma. It serves over 5,000 customers globally with no single customer accounting for more than 7% of net sales.

Key Financial Metrics

Margins (2007): Operating margin was 11.1% (up from 10.1% in 2006). Net income margin was 7.5% (up from 6.4% in 2006).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 18% to nearly $1.9 billion. Approximately 7% of this growth was due to favorable foreign exchange rates (weakening U.S. dollar vs. Euro), 1% from acquisitions, and the remaining 10% from increased demand, particularly in the Pharma and Beauty & Home segments.
• Profitability: Operating income rose 30% to $210.7 million. This was driven by higher sales volumes, better leverage of fixed costs, and a favorable product mix (higher-margin pharmaceutical sales). Segment income for Pharma increased 31%, Beauty & Home 38%, and Closures 14%.
• Cost Pressures: Cost of sales as a percentage of net sales increased slightly to 67.9% due to rising raw material costs (plastic resin and metals) and LIFO inventory valuation impacts, partially offset by volume leverage and lower compliance costs in the Pharma segment compared to 2006.
• Discontinued Operations: The company sold its Australian operation in Q4 2007, generating a net gain of $2.2 million.

Guidance, Outlook, and Risks

Outlook and Guidance:

• 2008 Sales: Management anticipates sales increases in all segments, driven by growth in developing markets and inflation-resistant product demand.
• Q1 2008 EPS: Diluted earnings per share are expected to be in the range of $0.46 to $0.49, compared to $0.41 in Q1 2007.
• Tax Rate: The effective tax rate for 2008 is expected to be between 30% and 31%.
• Capital Expenditures: Estimated at approximately $170 million for 2008.

Key Risks and Contingencies:

• Raw Material Costs: Continued increases in resin and metal prices could negatively impact margins if not fully passed on to customers.
• Foreign Exchange: While a weaker dollar boosts reported revenue, it increases the cost of European-produced goods sold in the U.S., potentially compressing margins.
• Goodwill Impairment: The company holds $222.7 million in goodwill. Management notes that a 61% reduction in estimated cash flows for one reporting unit could trigger an impairment test, potentially risking up to $38.7 million in write-downs.
• Customer Concentration: While no single customer exceeds 7%, consolidation in the customer base could lead to pricing pressures.

Investor Verification Checklist

• Raw Material Hedging: Verify the extent to which price increases for plastic resins and metals have been successfully passed through to customers in 2008.
• Pharma Segment Growth: Confirm the sustainability of the 22% sales growth in the Pharma segment, which relies heavily on new customer launches and MDI valve demand.
• Goodwill Valuation: Review the assumptions used in the discounted cash flow model for the reporting unit with the smallest excess of fair value over carrying value.
• Foreign Currency Impact: Monitor the net impact of the Euro/U.S. dollar exchange rate on operating margins, given the company's status as a net importer from Europe.
• Capital Allocation: Track the execution of the $170 million capital expenditure plan and its impact on capacity for high-growth products.